Literature DB >> 15684568

Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats.

Masatoshi Inden1, Jun-Ichi Kondo, Yoshihisa Kitamura, Kazuyuki Takata, Kaneyasu Nishimura, Takashi Taniguchi, Hideyuki Sawada, Shun Shimohama.   

Abstract

Parkinson's disease is characterized by dopaminergic neuronal death and the presence of Lewy bodies in the substantia nigra pars compacta (SNpc). alpha-Synuclein and ubiquitin are components of Lewy bodies, but the process of Lewy body formation and the relationship between inclusion formation and dopaminergic neuronal death have not been resolved. In this study, unilateral intranigral microinjection of 6-hydroxydopamine caused a significant loss of tyrosine hydroxylase-immunopositive neurons in both the substantia nigra and striatum and apomorphine-induced contralateral rotation. The co-administration of proteasome inhibitors, such as lactacystin or carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132), significantly prevented both dopaminergic neurodegeneration and apomorphine-induced rotational asymmetry. Proteasome inhibitors markedly formed intracellular protein inclusions labeled by thioflavin-S in the SNpc. Inclusion-like immunoreactivities for alpha-synuclein and ubiquitin were detected after 4 weeks. These results suggest that proteasome plays an important role in both the early phase of dopaminergic neuronal death and inclusion body formation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15684568     DOI: 10.1254/jphs.fp0040525

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  10 in total

1.  Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration.

Authors:  Brian N Mathur; M Diana Neely; Melanie Dyllick-Brenzinger; Anurag Tandon; Ariel Y Deutch
Journal:  Brain Res       Date:  2007-07-20       Impact factor: 3.252

2.  Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.

Authors:  Naoto Kadoguchi; Hiroki Kimoto; Ryohei Yano; Hiroyuki Kato; Tsutomu Araki
Journal:  Metab Brain Dis       Date:  2008-04-19       Impact factor: 3.584

3.  Adaptation to chronic MG132 reduces oxidative toxicity by a CuZnSOD-dependent mechanism.

Authors:  Rehana K Leak; Michael J Zigmond; Anthony K F Liou
Journal:  J Neurochem       Date:  2008-05-03       Impact factor: 5.372

4.  Selective susceptibility of human dopaminergic neural stem cells to dopamine-induced apoptosis.

Authors:  Sung-Man Jeon; Sang-Myung Cheon; Hye-Rahn Bae; Jae Woo Kim; Seung U Kim
Journal:  Exp Neurobiol       Date:  2010-12-31       Impact factor: 3.261

5.  Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease.

Authors:  Jolanta Konieczny; Danuta Jantas; Tomasz Lenda; Helena Domin; Anna Czarnecka; Katarzyna Kuter; Maria Śmiałowska; Władysław Lasoń; Elżbieta Lorenc-Koci
Journal:  Neurotox Res       Date:  2014-05-20       Impact factor: 3.911

6.  Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synuclein.

Authors:  Eduard Bentea; Anke Van der Perren; Joeri Van Liefferinge; Anissa El Arfani; Giulia Albertini; Thomas Demuyser; Ellen Merckx; Yvette Michotte; Ilse Smolders; Veerle Baekelandt; Ann Massie
Journal:  Front Behav Neurosci       Date:  2015-03-31       Impact factor: 3.558

7.  Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo.

Authors:  Reinis Svarcbahs; Ulrika H Julku; Susanna Norrbacka; Timo T Myöhänen
Journal:  Sci Rep       Date:  2018-01-24       Impact factor: 4.379

Review 8.  The Proteasome Inhibition Model of Parkinson's Disease.

Authors:  Eduard Bentea; Lise Verbruggen; Ann Massie
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

9.  Ubiquitin-proteasome system impairment and MPTP-induced oxidative stress in the brain of C57BL/6 wild-type and GSTP knockout mice.

Authors:  Andreia Neves Carvalho; Carla Marques; Elsa Rodrigues; Colin J Henderson; C Roland Wolf; Paulo Pereira; Maria João Gama
Journal:  Mol Neurobiol       Date:  2012-11-06       Impact factor: 5.590

10.  Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs.

Authors:  Thea P Lillethorup; Andreas N Glud; Aage K O Alstrup; Ove Noer; Erik H T Nielsen; Anna C Schacht; Natalie Landeck; Deniz Kirik; Dariusz Orlowski; Jens Christian H Sørensen; Doris J Doudet; Anne M Landau
Journal:  Sci Rep       Date:  2018-10-24       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.